PepGen (PEPG)
Develops peptide-enabled oligonucleotide therapies with a clinical focus on myotonic dystrophy type 1.
$2.79
vs last close−0.19 (−6.54%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 75.17% | 52.06M shares | |
|---|---|---|---|
| 74 holders · as of Jun 30, 2026 | |||
| Insiders | 0.89% | 614.9K shares | |
| 6 holders · as of May 26, 2026 | |||
| Strategic holders | 7.15% | 4.96M shares | |
| 1 holder · as of Oct 1, 2025 | |||
| Other | 16.79% | 11.63M shares | |
| remainder | |||
69.26M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
13F, as of Jun 30, 2026
74 holders · 52.06M shares · 7 new positions · 30 increased · 23 reduced · 30 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Ra Capital Management, L.P. | 20.06M | 28.97% | 0 | Aug 14, 2026 |
| Commodore Capital LP | 4.48M | 6.46% | 0 | Aug 14, 2026 |
| Viking Global Investors LP | 3.48M | 5.03% | 0 | Aug 14, 2026 |
| Laurion Capital Management LP | 2.75M | 3.97% | 0 | Aug 13, 2026 |
| Adar1 Capital Management, LLC | 2.59M | 3.74% | +983.4K | Aug 14, 2026 |
| Vivo Capital, LLC | 2.33M | 3.36% | 0 | Aug 14, 2026 |
| Vanguard Capital Management LLC | 1.94M | 2.80% | −1.8K | Aug 13, 2026 |
| Millennium Management LLC | 1.79M | 2.58% | −292.4K | Aug 14, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| RA Capital Management, L.P.incl. RA Capital Healthcare Fund, L.P., Peter Kolchinsky +1 more | 29.20% | 20.10M | 13D | Sep 30, 2025 |
| Oxford Science Enterprises plc | 7.20% | 4.96M | 13G | Oct 1, 2025 |
| Ein #incl. Janus Henderson Biotech Innovation Master Fund Ltd, Janus Henderson Group plc | 7.20% | 2.34M | Nov 14, 2024 | |
| Commodore Capital LP | 6.50% | 4.48M | 13G | May 15, 2026 |
| Viking Global Investors LP | 5.03% | 3.48M | 13G | May 15, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| May 21, 2026 | Kasra Kasraianofficer: Chief Technical Officer | Sale | 1,233 | $1.41 | 50,074 |
| Mar 4, 2026 | James G. McArthurdirector, officer: President and CEO | Sale · 2 lots | 5,275 | $6.23 | 296,326 |
| Mar 4, 2026 | Noel Donnellyofficer: Chief Financial Officer | Sale · 2 lots | 2,084 | $6.23 | 111,603 |
| Mar 4, 2026 | Paul Streckofficer: EVP, Head of R&D | Sale · 2 lots | 1,879 | $6.23 | 76,226 |
| Sep 30, 2025 | Oxford Science Enterprises plcother: Former 10% Owner | Purchase | 200,000 | $3.20 | 4,955,388 |
| Sep 26, 2025 | Ra Capital Management, L.P.director, 10 percent owner: | Purchase | 9,375,000 | $3.20 | 18,554,273 |
House and Senate disclosures
Not reported.